VIELABIO

January 2021

Forward-Looking Statements

This presentation contains forward-looking statements that involve substantial risk and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements although not all forward-looking statements contain these identifying words. Forward-looking statements contained in this presentation include, but are not limited to, statements regarding: our expectations regarding the commercialization and market acceptance of UPLIZNA®; our belief that UPLIZNA® provides prescribing physicians with an important new treatment option for patients with NMOSD; strategy, future operations, prospects, plans, objectives of management, the timing and progress of clinical development and potential commercialization of our product candidates, if approved; our belief that UPLIZNA® could reduce attacks that can lead to devastating and irreversible disability in patients with NMOSD; our estimate of the percentage of patients with NMOSD that test positive for anti-AQP4 antibodies; potential benefits of UPLIZNA®; our expectations regarding the availability of UPLIZNA®; statements regarding market access and medical coverage for UPLIZNA®; our expectations with respect to the potential regulatory approval and commercialization of inebilizumab outside of the United States; our planned and ongoing clinical trials for our product candidates and the potential advantages of those product candidates, including inebilizumab, VIB4920 and VIB7734; the initiation, enrollment, timing, progress, release of data from and results of those planned, ongoing, and completed clinical trials; our goals with respect to the development and potential use, if approved, of each of its product candidates; the utility of prior non-clinical and clinical data in determining future clinical results; our expectations about sufficiency of our existing cash balance; the anticipated impact of the COVID-19 pandemic on our commercialization efforts, business operations and clinical trials; and the expected timing and the potential for payments under our collaboration agreements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, the risks and uncertainties around the duration and severity of the novel coronavirus outbreak and impact of it and COVID-19 on our product candidates’ clinical trials, development and, if approved, commercialization plans and business operations and those set forth in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission on March 25, 2020, as well as any updates to those risk factors filed from time to time in our periodic and current reports.

Our Clinical Approach

Focused on three biological pathways shared across various diseases

Autoantibody pathway

Inebilizumab

Autoantibodies, secreted by a subset of B cells (plasmablasts, plasma cells), attack native tissues as opposed to foreign pathogens

CD40/CD40L co-stimulatory pathway

VIB4920

Overstimulation of immune cells can be triggered by interaction of CD40/CD40L, leading to immune response cascade and overproduction of molecules that mediate inflammation

Innate cytokine pathway

VIB7734

Overproduction of pro-inflammatory cytokines secreted by pDCs (type I interferons, IL-6, TNFα)



Building a Leading Pathway-Centric Pipeline

MOLECULE *(mechanism)*	INDICATION	DEVELOPMENT STAGE	STATUS	GLOBAL RIGHTS
		PRECLINICAL / PHASE 1 / PHASE 2 / PHASE 3 / APPROVED		
Inebilizumab-cdon (Anti-CD19 mAb)	Neuromyelitis Optica Spectrum Disorder		uplizna® inebilizumab-cdon U.S. FDA Approval in June 2020	VIELA BIO[1]
	Myasthenia Gravis		Phase 3 Trial	VIELA BIO
	IgG4-Related Disease		Phase 3 Trial	VIELA BIO
	Kidney Transplant Desensitization		Phase 2 Trial	VIELA BIO
VIB4920 (Anti-CD40L-Tn3 Fusion Protein)	Sjögren's Syndrome		Phase 2b Trial	VIELA BIO
	Kidney Transplant Rejection		Phase 2 Trial	VIELA BIO
	Rheumatoid Arthritis		Phase 2 Trial	VIELA BIO
VIB7734 (Anti-ILT7 mAb)	Systemic Lupus Erythematosus		Phase 2 Trial (planned)	VIELA BIO
	Cutaneous Lupus Erythematosus		Phase 1b Trial	VIELA BIO
	COVID-19-Related Acute Lung Injury		Phase 1 Trial	VIELA BIO
VIB1116	Undisclosed		IND Submitted	VIELA BIO

[1] We have entered into collaboration agreements with Hansoh Pharmaceutical Group and Mitsubishi Tanabe Pharma to develop and market inebilizumab in China, Hong Kong and Macau and Japan and other Asia countries, respectively.

UPLIZNA™ Now Available in U.S.

uplizna™
inebilizumab-cdon

First and only B cell depleter approved for treatment of NMOSD in adults who are anti-aquaporin-4 (AQP4) antibody positive

- **Efficacy:** 89% of clinical trial patients were attack-free at end of control period (treated with UPLIZNA™ as monotherapy); reduction in hospitalizations
- **Safety:** Favorable profile; no “black box” warning
- **Dosing Schedule:** Maintenance dosing once every six months after initial doses
- **Mechanism-of-Action:** Efficiently depletes broad range of B cells via CD19

Important Safety Information
For Important Safety Information and Prescribing Information, please visit UPLIZNA.com

Upcoming Corporate Priorities

UPLIZNA® commercialization

Inebilizumab additional indications:

- Continue patient enrollment in Phase 3 trials in MG and IgG4-RD

VIB4920:

- Continue patient enrollment in Sjögren's syndrome, RA, and kidney transplant rejection trials

VIB7734:

- Prepare for Phase 2 trial in SLE (H1 2021)
- Continue patient enrollment in Phase 1 trial for COVID-19-related acute lung injury

Preclinical:

- Submitted IND for VIB1116

VIELABIO